210 related articles for article (PubMed ID: 11748663)
1. Parenteral and oral immunization with a plasmid DNA expressing the human papillomavirus 16-L1 gene induces systemic and mucosal antibodies and cytotoxic T lymphocyte responses.
Rocha-Zavaleta L; Alejandre JE; Garcia-Carranca A
J Med Virol; 2002 Jan; 66(1):86-95. PubMed ID: 11748663
[TBL] [Abstract][Full Text] [Related]
2. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes.
Dupuy C; Buzoni-Gatel D; Touzé A; Bout D; Coursaget P
J Virol; 1999 Nov; 73(11):9063-71. PubMed ID: 10516012
[TBL] [Abstract][Full Text] [Related]
3. Plasmid encoding papillomavirus Type 16 (HPV16) DNA constructed with codon optimization improved the immunogenicity against HPV infection.
Cheung YK; Cheng SC; Sin FW; Xie Y
Vaccine; 2004 Dec; 23(5):629-38. PubMed ID: 15542183
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus type 16 L1 capsomeres induce L1-specific cytotoxic T lymphocytes and tumor regression in C57BL/6 mice.
Ohlschläger P; Osen W; Dell K; Faath S; Garcea RL; Jochmus I; Müller M; Pawlita M; Schäfer K; Sehr P; Staib C; Sutter G; Gissmann L
J Virol; 2003 Apr; 77(8):4635-45. PubMed ID: 12663770
[TBL] [Abstract][Full Text] [Related]
5. Enhanced mucosal and systemic immune responses following intravaginal immunization with human papillomavirus 16 L1 virus-like particle vaccine in thermosensitive mucoadhesive delivery systems.
Park JS; Oh YK; Kang MJ; Kim CK
J Med Virol; 2003 Aug; 70(4):633-41. PubMed ID: 12794729
[TBL] [Abstract][Full Text] [Related]
6. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
7. Nasal immunization of mice with peptide having a cross-neutralization epitope on minor capsid protein L2 of human papillomavirus type 16 elicit systemic and mucosal antibodies.
Kawana K; Kawana Y; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
Vaccine; 2001 Jan; 19(11-12):1496-502. PubMed ID: 11163673
[TBL] [Abstract][Full Text] [Related]
8. Immunization against human papillomavirus infection and associated neoplasia.
Osen W; Jochmus I; Müller M; Gissmann L
J Clin Virol; 2000 Oct; 19(1-2):75-8. PubMed ID: 11091150
[TBL] [Abstract][Full Text] [Related]
9. Vaccine regimen for prevention of sexually transmitted infections with human papillomavirus type 16.
Kowalczyk DW; Wlazlo AP; Shane S; Ertl HC
Vaccine; 2001 May; 19(25-26):3583-90. PubMed ID: 11348726
[TBL] [Abstract][Full Text] [Related]
10. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response.
Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM
Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545
[TBL] [Abstract][Full Text] [Related]
11. A human papillomavirus type 16 vaccine by oral delivery of L1 protein.
Sasagawa T; Tani M; Basha W; Rose RC; Tohda H; Giga-Hama Y; Azar KK; Yasuda H; Sakai A; Inoue M
Virus Res; 2005 Jun; 110(1-2):81-90. PubMed ID: 15845258
[TBL] [Abstract][Full Text] [Related]
12. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
[TBL] [Abstract][Full Text] [Related]
13. Enhanced mucosal and systemic immunogenicity of human papillomavirus-like particles encapsidating interleukin-2 gene adjuvant.
Oh YK; Sohn T; Park JS; Kang MJ; Choi HG; Kim JA; Kim WK; Ko JJ; Kim CK
Virology; 2004 Oct; 328(2):266-73. PubMed ID: 15464846
[TBL] [Abstract][Full Text] [Related]
14. A novel mucosal vaccine based on live Lactococci expressing E7 antigen and IL-12 induces systemic and mucosal immune responses and protects mice against human papillomavirus type 16-induced tumors.
Bermúdez-Humarán LG; Cortes-Perez NG; Lefèvre F; Guimarães V; Rabot S; Alcocer-Gonzalez JM; Gratadoux JJ; Rodriguez-Padilla C; Tamez-Guerra RS; Corthier G; Gruss A; Langella P
J Immunol; 2005 Dec; 175(11):7297-302. PubMed ID: 16301635
[TBL] [Abstract][Full Text] [Related]
15. Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.
Kuck D; Lau T; Leuchs B; Kern A; Müller M; Gissmann L; Kleinschmidt JA
J Virol; 2006 Mar; 80(6):2621-30. PubMed ID: 16501072
[TBL] [Abstract][Full Text] [Related]
16. Boosting with recombinant vaccinia increases HPV-16 E7-specific T cell precursor frequencies of HPV-16 E7-expressing DNA vaccines.
Chen CH; Wang TL; Hung CF; Pardoll DM; Wu TC
Vaccine; 2000 Apr; 18(19):2015-22. PubMed ID: 10706963
[TBL] [Abstract][Full Text] [Related]
17. Generation and characterization of a preventive and therapeutic HPV DNA vaccine.
Kim D; Gambhira R; Karanam B; Monie A; Hung CF; Roden R; Wu TC
Vaccine; 2008 Jan; 26(3):351-60. PubMed ID: 18096279
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus type 16 virus-like particles expressed in attenuated Salmonella typhimurium elicit mucosal and systemic neutralizing antibodies in mice.
Nardelli-Haefliger D; Roden RB; Benyacoub J; Sahli R; Kraehenbuhl JP; Schiller JT; Lachat P; Potts A; De Grandi P
Infect Immun; 1997 Aug; 65(8):3328-36. PubMed ID: 9234794
[TBL] [Abstract][Full Text] [Related]
19. HPV-16 L1 genes with inactivated negative RNA elements induce potent immune responses.
Rollman E; Arnheim L; Collier B; Oberg D; Hall H; Klingström J; Dillner J; Pastrana DV; Buck CB; Hinkula J; Wahren B; Schwartz S
Virology; 2004 Apr; 322(1):182-9. PubMed ID: 15063127
[TBL] [Abstract][Full Text] [Related]
20. DNA vaccination of mice with plasmid expressing human papillomavirus 6 major capsid protein L1 elicits type-specific antibodies neutralizing pseudovirions constructed in vitro.
Matsumoto K; Kawana K; Yoshikawa H; Taketani Y; Yoshiike K; Kanda T
J Med Virol; 2000 Feb; 60(2):200-4. PubMed ID: 10596021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]